• Translating the
    Library of Life
    into transformative therapeutics.

    Read more

  • Learning from the
    Memory of Life
    to develop novel therapies for Alzheimer’s.

    Read more

  • Neurimmune’s anti-alpha-
    synuclein antibody
    program for Parkinson in Phase 2.

    Read more

  • Neurimmune's anti-SOD1
    antibody program for ALS
    in Phase 1. Read more


Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics.

Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune collaborates on aducanumab with Biogen who co-develops it with Eisai.

Aducanumab is a human monoclonal antibody removing beta amyloid in brains of patients with Alzheimer’s disease. Based on large Phase 3 study results showing clinical benefit, Biogen plans regulatory filing for aducanumab in Alzheimer’s disease.

Neurimmune's Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials.